Estrella Immunopharma, Inc.
ESLAHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Estrella Immunopharma, Inc. (ESLA) is listed under Biotechnology. Valued at $42.8M, ESLA is a micro-cap name in its sector. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Market Cap
$42.8M
Beta
0.93
P/E (TTM)
—
P/E (Fwd)
-3.08
EPS (TTM)
$-0.25
EPS (Fwd)
$-0.32
ROE
—
ROA
-251.9%
Cash
$146,670
Total Debt
$0
Free CF
-$6.8M
52W Change
-56.8%
Annual Financials
Cash vs Debt
Where ESLA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ESLA finished 60.42% below its 150-day moving average ($0.96) and 62.38% below its 200-day moving average ($1.01). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ESLA overbought or oversold?
At the October 20, 2026 close, ESLA's RSI(14) was 42.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Estrella Immunopharma, Inc. reports $147K in cash and $0 in total debt. Free cash flow is running at -$6.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ESLA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.